Literature DB >> 8123190

Monoaminergic activities in Lewy body dementia: relation to hallucinosis and extrapyramidal features.

E K Perry1, E Marshall, P Thompson, I G McKeith, D Collerton, A F Fairbairn, I N Ferrier, D Irving, R H Perry.   

Abstract

Serotonergic (5-HT) and dopaminergic activities have been examined in Lewy Body Dementia (LBD) and compared with Parkinson's disease (PD) and Alzheimer's disease (AD). In the neocortex the LBD subgroup experiencing hallucinations was distinguished from the other categories by an increase in the 5HIAA:5HT ratio measured in frontal cortex and by the serotonergic (5-HIAA or 5-HIAA:5-HT): cholinergic (choline acetyltransferase) ratio in frontal and temporal cortex. In the neostriatum (caudate nucleus), loss of dopamine and increased HVA:dopamine ratio correlated with the reduction in substantia nigra neurons in LBD but not PD, despite the greater loss of neurones and dopamine and the higher dopamine turnover ratio in PD. LBD patients experiencing severe Parkinsonism as a result of neuroleptic treatment tended to have lower neuron counts, in combination with higher turnover ratios, than the remainder. Qualitative differences between LBD and PD included decreased cortical 5-HT turnover in PD compared with the increase in LBD. There were no significant changes in any parameter in AD, with the exception of a reduction in temporal cortex 5HIAA. The results suggest that although the neurochemical pathology of LBD and PD involves similar systems, the nature of the derangements differs sufficiently between the diseases to account for differences in symptomatology.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8123190     DOI: 10.1007/bf02260919

Source DB:  PubMed          Journal:  J Neural Transm Park Dis Dement Sect        ISSN: 0936-3076


  11 in total

Review 1.  Neuropsychiatric aspects of Alzheimer's disease.

Authors:  C Ballard; M Walker
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

2.  Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease.

Authors:  A Moser; F Siebecker; P Vieregge; P Jaskowski; D Kömpf
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 3.  The basis for behavioural disturbances in dementia.

Authors:  M M Esiri
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-08       Impact factor: 10.154

4.  Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease.

Authors:  T Büttner; W Kuhn; T Müller; F L Welter; J Federlein; K Heidbrink; H Przuntek
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 5.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

6.  Effect of oral administration of zanapezil (TAK-147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats.

Authors:  Izzettin Hatip-Al-Khatib; Katsunori Iwasaki; Yoshitaka Yoshimitsu; Takashi Arai; Nobuaki Egashira; Kenichi Mishima; Tomoaki Ikeda; Michihiro Fujiwara
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

Review 7.  Neuropsychiatric aspects of dementia with Lewy bodies.

Authors:  N Hirono; J L Cummings
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

Review 8.  Dementia-related psychosis and the potential role for pimavanserin.

Authors:  Jeffery L Cummings; D P Devanand; Stephen M Stahl
Journal:  CNS Spectr       Date:  2020-08-19       Impact factor: 3.790

9.  Brain aging research at the close of the 20th century: from bench to bedside.

Authors:  C Cidis Meltzer; P T Francis
Journal:  Dialogues Clin Neurosci       Date:  2001-09       Impact factor: 5.986

10.  Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia.

Authors:  Amani Alghamdi; Julie Vallortigara; David R Howlett; Martin Broadstock; Tibor Hortobágyi; Clive Ballard; Alan J Thomas; John T O'Brien; Dag Aarsland; Johannes Attems; Paul T Francis; David R Whitfield
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.